FDA Inspection 1297784 — Takeda Pharmaceutical Company d.b.a. BioLife Plasma Services LP
The FDA completed an inspection of Takeda Pharmaceutical Company d.b.a. BioLife Plasma Services LP on December 5, 2025 in Kansas City, MO. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- December 5, 2025
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Kansas City, MO (United States)